Related Experiment Video
Updated: Aug 7, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
[Generic drug policy implementation in Brazil]
Cláudia Regina Cilento Dias1, Nicolina Silvana Romano-Lieber
1Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, Brasil.
Cadernos De Saude Publica
|July 13, 2006
Summary
Brazil's generic drug policy, implemented in 1999, saw significant market growth due to legislative adaptation and government support. While access to medicines didn't rise, affordable, quality-assured generic drugs became available.
Area of Science:
- Health Policy
- Pharmaceutical Economics
- Public Health
Context:
- Brazil implemented a national generic drug policy in 1999.
- The policy's rollout involved complex political and administrative stages.
- Legislation for generic drugs was approved between 1999 and 2002.
Purpose:
- To describe the implementation process of Brazil's generic drug policy.
- To examine the evolution of generic drug legislation in Brazil.
- To analyze the factors contributing to the success of the generic drug policy.
Summary:
- The study details the implementation of Brazil's generic drug policy, analyzing legislation from 1999-2002.
- Key success factors included ongoing legislative adaptation, media support, and government engagement.
- A mixed-methods approach involved analyzing periodical articles and interviewing key stakeholders.
Impact:
- Generic drugs rapidly acquired a substantial market share in Brazil.
- The policy resulted in more affordable medicines with assured quality and interchangeability.
- Population access to medicines did not significantly increase, despite policy implementation.
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:17Drug Nomenclature
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...